Skip to content

SPAC Feed

Curated SPACs News

  • News
  • Opinions
  • Events
  • Videos
  • Resources
  • Contact Us
  • News
 Posted on October 19, 2026

Investment firm TCGX picks migraine biotech TriGemX to take public via SPAC – Fierce Biotech

Investment firm TCGX picks migraine biotech TriGemX to take public via SPAC  Fierce Biotech
By sf-admin

Post navigation

TriGemX Bio is going public through SPAC to get its migraine prospect to market – Endpoints News
ICR, the leading Capital Markets Communications and Advisory Firm, Publishes its Q3 2026 SPAC Market Update & Outlook – Business Wire


  • About Us
  • Contact Us
  • Subscribe
Copyright © 2026 SPAC Feed. All Rights Reserved | News Vibe by Theme Palace